Premature Ovarian Failure – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Premature Ovarian Failure – Drugs In Development, 2024 report and make more profitable business decisions.
Premature Ovarian Failure also known as primary ovarian insufficiency (POI) is a condition where a women’s ovary tends to stop working in their 40s. It can also be defined as cessation of menses for more than 1 year before 40 years of age. It is not completely related to menopause, where women have fewer eggs. It can be autoimmune, or due to underlying conditions primarily women with thyroid disease. Irregular periods, decreased libido, hot flashes, night sweats, and fertility are the symptoms associated with this condition. Differential diagnosis to rule out pregnancy followed by serum follicle-stimulating hormone (FSH) level, serum estradiol level, luteinizing hormone level, TSH profile, creatinine levels, and glucose levels are investigated. Hormonal therapy with estrogens, underlying disease treatment, and supportive therapy as needed. Cryopreservation is chosen in women with the risk of developing infertility.
The Premature Ovarian Failure drugs in development market research report provide comprehensive information on the therapeutics under development for Premature Ovarian Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Ovarian Failure and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Premature Ovarian Failure | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Premature Ovarian Failure therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Premature Ovarian Failure pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Premature Ovarian Failure treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Asia Stem Cell Regenerative Pharmaceutical Co LtdBrigham and Women's Hospital
CHA Biotech Co Ltd
Creative Medical Technology Holdings Inc
Exorphia Co Ltd
Follitech AB
iCELL Biotechnology Co Ltd
ImmuneCyte Inc
Multipotent Stem Cell Regenerative Medicine Technology Guangzhou Co Ltd
Qurgen Inc
VCANBIO Cell and Gene Engineering Corp Ltd
Vitti Labs LLC
YB Life Science LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Premature Ovarian Failure reports